04 Apr

Allergen-Induced Bronchoconstriction in Asthmatic Children (7)

Allergen-Induced Bronchoconstriction in Asthmatic Children (7)BN52021 at the concentration of 50 ng/ml had only a little effect on PAF-induced bronchospasm; at a concentration of 150 ng/ml, BN52021 could inhibit PAF-induced bronchospasm in four of the six responders and at a concentration of450 ng/ml, BN52021 was capable of preventing PAF-induced bronchospasm in all six responders. However, as the dose-response study of BN52021 was done successively, a cumulative effect of BN52021 should be considered. After the dose-dependent nature of inhibitory effect of BN52021 on PAF-induced bronchospasm was established, BN52021 at a concentration of450 ng/ml was used in the methacholine and allergen challenge studies.
The specificity of the inhibitory effect of BN52021 on PAF-induced bronchospasm was studied by using methacholine challenge. Figure 2 shows that there was no difference in methacholine PD20 units between placebo and BN52021 pretreated groups (40.8 ±20.2 U vs 41.2 ±20.6 U).
To study the possible role of PAF in the pathogenesis of allergic bronchial asthma — Buy Advair Diskus Online, a double-blind, placebo-controlled, crossover allergen challenge study was conducted. Patients were instructed to inhale either BN52021 or placebo and then perform the allergen challenge. Two tests were done seven days apart.

Figure-2

Figure 2. Specificity of inhibitory effect of BN52021 on platelet-activating factor (PAF)-induced bronchoconstriction. Each subject inhaled either placebo (A) or BN52021 (B) in a double-blind, crossover fashion and then performed methacholine challenge. No difference in methacholine PD20 units was found between placebo group and BN52021 pretreated group. Thus, BN52021 had no protective effect on methacholine-induced bronchoconstriction.

© 2019 - Men’s Health Info Blog